Abstract:Pigment epithelium-derived factor (PEDF) was recently found to be closely associated with metabolic syndrome and insulin resistance. However, there is a lack of evidence quantitating PEDF levels in subjects with different glucose tolerance status and it is not known whether metformin treatment can affect PEDF concentrations. In this study, 517 Chinese subjects were categorized as having normal glucose tolerance (NGT), impaired glucose regulation (IGR), or type 2 diabetes mellitus (T2DM) using the guidelines of the International Diabetes Federation. In addition, 63 patients with newly diagnosed T2DM were treated for 24 weeks with metformin. Circulating PEDF concentrations and metabolic profiles were assessed. The study protocol was approved by the Ethics Committee of Drum Tower Hospital. Body mass index (BMI) classifications were in accordance with World Health Organization guidelines. Of the 517 participants (42.6% men, 57.4% women; mean [± SD] age 49.7 ± 14.5 years), 186 had NGT, 216 had IGR, and 169 had diabetes. Median serum PEDF concentrations were significantly higher in subjects with IGR (9.5 μg/mL; interquartile range [IQR] 7.6–11.4 μg/ mL) and T2DM (9.7 μg/mL; IQR 7.9–11.7 μg/mL), than in those with NGT (8.5 μg/mL; IQR 7.1–10.7 μg/mL; P = 0.010; Fig. 1a). For the metformin-treated group, PEDF concentrations were significantly lower after treatment in T2DM patients who lost weight (n = 47; from 9.2 [7.2–11.7] to 8.1 [6.2–9.9] μg/mL; P = 0.027), whereas there was no significant difference in PEDF concentrations before and after metformin treatment in the group of patients who did not lose weight on metformin treatment (n = 16; 9.1 [7.8–11.1] vs 10.6 [7.1–13.0] μg/mL, respectively; P > 0.05; Fig. 1b). Spearman correlation analysis demonstrated that PEDF concentrations were significantly correlated with risk factors for metabolic syndrome and visceral obesity (P < 0.001). In multiple stepwise regression, PEDF was associated with alanine aminotransferase (P < 0.001), triglycerides (P = 0.002) and diastolic blood pressure (P = 0.002) after adjustment for age and gender. Subjects in the second and third tertiles of PEDF concentrations (8.0–10.4 and 10.4–32.0 μg/mL, respectively) exhibited a higher prevalence of overweight or obesity than those in the first tertile (3.2–8.0 μg/mL; P < 0.001), and the prevalence of overweight or obesity was higher for those in the third tertile than in the second tertile. Furthermore, serum PEDF concentrations were significantly higher in men than in women (9.6 [7.9–11.9] vs 8.9 [7.4–10.8] μg/mL, respectively; P = 0.003) and this difference remained after adjusting for BMI, waist circumference, and the waist-to-hip ratio (P = 0.009; Fig. 1c). Estradiol concentrations were negatively associated with PEDF (r = −0.216, P = 0.013; Fig. 1d) and were independent determinants of PEDF in postmenopausal women. In conclusion, PEDF concentrations are significantly elevated in patients with glucose intolerance and could be reduced by metformin treatment in T2DM patients who lost weight while on metformin treatment. Some in vitro studies have suggested a link between estradiol and PEDF concentrations. To the best of our knowledge, the present study is the first to identify decreased estradiol as an independent risk factor for increased PEDF concentrations, which may contribute to the occurrence of T2DM in postmenopausal women.

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes

Serum Level of Pigment Epithelium-Derived Factor in Different Glucose Tolerance State

VEGF Levels in Plasma in Relation to Metabolic Control, Inflammation, and Microvascular Complications in Type-2 Diabetes A Cohort Study

The relations between serum pigment epithelium-derived factor and insulin resistance in type 2 diabetes

Elevated Plasma Concentrations of Pigment Epithelium‐derived Factor in Type 2 Diabetic Patients is Reduced by Metformin Treatment in Association with Weight Loss

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Correlation Between the Amplitude of Glucose Excursion and the Oxidative/antioxidative System in Subjects with Different Types of Glucose Regulation.

[Correlation Between the Amplitude of Glucose Excursion and Plasma 8-Iso Prostaglandin F2alpha Level in Subjects with Different Types of Glucose Regulation].

[Change and Significance of Serum Pigment Epithelium-Derived Factor in Type 2 Diabetic Nephropathy].

608-P: High er Level of Angiopoietin-Like Protein-2 Is Associated with Diabetic Macular Edema in Patients with Type 2 Diabetes Mellitus

C1q/TNF-Related Protein-3 (CTRP-3) and Pigment Epithelium-Derived Factor (PEDF) Concentrations in Patients with Gestational Diabetes Mellitus: A Case-Control Study

Relationships Between Glucose Excursion and the Activation of Oxidative Stress in Patients with Newly Diagnosed Type 2 Diabetes or Impaired Glucose Regulation

Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes – mediation by pigment epithelium-derived factor

C1q/TNF-Related Protein-3 (CTRP-3) and Pigment Epithelium-Derived Factor (PEDF) Concentrations in Patients With Type 2 Diabetes and Metabolic Syndrome

Circulating 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) levels are associated with hyperglycemia and β cell dysfunction in a Chinese population

Circulating 3-Carboxy-4-Methyl-5-Propyl-2-Furanpropanoic Acid (Cmpf) Levels Are Associated With Hyperglycemia And Beta Cell Dysfunction In A Chinese Population

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus

[Effects of Insulin on Pigment Epithelium-Derived Factor Expression in Adipocytes of Type 2 Diabetic Mellitus in Rats].

The Contribution of Postprandial Glucose Levels to Hyperglycemia in Type 2 Diabetes Calculated from Continuous Glucose Monitoring Data: Real World Evidence from the DIALECT-2 Cohort

Plasma Prostaglandin E2 Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation

THE ASSOCIATION OF DECREASED SERUM GDNF LEVEL WITH HYPERGLYCEMIA AND DEPRESSION IN TYPE 2 DIABETES MELLITUS